MediWound (MDWD)
Clears burn eschar and chronic wounds with enzymatic technology instead of surgery.
Something off on this page? Send us feedback.
Sells an approved enzymatic biologic that clears burn eschar without surgery and develops a Phase III chronic-wound candidate on the same platform, earning royalties and profit share through North American partner Vericel alongside government contracts and direct international sales, all produced at one manufacturing site in Israel.
One bromelain-derived enzyme platform underlies three products at different stages: NexoBrid, an approved biologic that clears burn eschar without surgery; EscharEx, in a global Phase III trial for venous leg ulcers; and MW005, an early skin-cancer candidate.
Regional partners carry distribution instead of an owned salesforce: Vericel in North America, Kaken in Japan, Mankind in India, and PolyMedics International in Europe, with the approved-country footprint wider than the still-ramping U.S. launch.
A run of successful pivotal trials backs clearances from the FDA, EMA, and Japan's PMDA, all produced at one vertically integrated plant in Yavne, Israel. U.S. revenue arrives as royalties and profit share through Vericel rather than direct sales, government contracts with BARDA and the Department of Defense add a further layer, and filings run on Form 20-F as a foreign private issuer with a single reportable segment.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Reiterate | Outperform | $32 | $30 |
| May 28, 2026 | Industrial Alliance Securities | Target | $22 | ||
| May 27, 2026 | Oppenheimer | Target | $36 | $32 | |
| Nov 21, 2025 | H.C. Wainwright | Target | $31 | $36 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $35.3M · Total debt $9.5M · Total assets $71.9M · Shareholders' equity $35.6M
- Revenue
- $3.1M
- Operating income
- −$9.5M
- Net income
- −$7.4M
No dividends on record.
| Institutions83 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 45.54% | 5.84M ADS | |
| Insiders11 holders · as of Sep 2, 2026 | 9.19% | 1.18M ADS | |
| Otherremainder | ≈ 45.27% | 5.81M ADS |
12.84M ADS as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
HOLD Alapkezelo Zrt.Insider | 8.10% | 1.04M | 13Gfiled Feb 13, 2026 ↗ |
Investor ABInstitution | 6.79% | 872,093 ADS | 13Fas of Jun 30, 2026 |
Yelin Lapidot Holdings Management Ltd.Institution | 5.91% | 758,169 ADS | 13Fas of Jun 30, 2026 |
Rosalind Advisors, Inc.Institution | 5.84% | 749,054 ADS | 13Fas of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 4.99% | 641,075 ADS | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Samuel Rubinstein | director | +525 | $12.62 |
| Sep 1, 2026 | Samuel Rubinstein | director | −525 | $12.72 |
| Aug 27, 2026 | Shmuel Hess | officer: COO & Chief Commercial Officer | −3,958 | $12.92 |
| Aug 26, 2026 | Shmuel Hess | officer: COO & Chief Commercial Officer | −1,865 | $13.00 |
| Jun 3, 2026 | Nachum Shamir | director | +6,000 | $14.00 |
- Smith & Nephew (ADR)
Markets SANTYL, the collagenase leader EscharEx is designed to challenge.
- Vericel
Runs the exclusive U.S. NexoBrid channel and sells a rival burn-care product.
- MiMedx
Scaled placental-allograft wound franchise that also supplies the VALUE trial.
- Organogenesis
Markets Apligraf and Dermagraft skin substitutes for the same VLU/DFU patients.
- Solventum
Fields V.A.C. negative-pressure therapy as an alternative debridement pathway.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MediWound | $13.08 | +3.65% | $167.8M | — | — | 14.1 | −45.8% |
| Smith & Nephew (ADR) | $28.58 | −0.34% | $12.04B | 19.0 | — | 1.9 | +3.7% |
| Vericel | $41.50 | +1.42% | $2.09B | 87.4 | 61.6 | 6.8 | +22.5% |
| MiMedx | $4.56 | +1.00% | $663.2M | 113.8 | 107.3 | 1.9 | −34.7% |
| Organogenesis | $1.68 | +2.76% | $214.9M | — | — | 0.5 | −56.7% |
| Solventum | $91.90 | −0.01% | $15.91B | 11.2 | 13.6 | 1.9 | +2.2% |
| Median | 53.2 | 61.6 | 1.9 | +2.2% |